ArticleFrontiers in oncology2025
Diagnostic significance of the novel biomarker combination for early-stage non-small cell lung cancer detection: results of the blind clinical study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: NSCLC can be cured in up to 65% of cases if detected early. However, most of the lung cancer (LC) cases are diagnosed at an advanced stage. Objective: The assessment of various tumor markers in retrospective double-blind clinical study and their possible combinations for detection of early-staged non-small cell lung cancer (NSCLC); evaluation of the best TM panel as a pre-screening tool for LC before Low-Dose CT scan; the development of the protocol for future prospective clinical study. Methods: A double-blind clinical study was conducted on 304 clinically verified patients, including 141 NSCLC, 133 healthy volunteers and 30 patients with COPD. Quantitative measurement of various TM was carried out using commercial immunoassays. Results: Unlike other tumor markers, which are expressed proportionally to the tumor growth, CA-62 demonstrated the highest values at Stage I and II of NSCLC. The use of CA-62 for early-staged NSCLC achieves 92% sensitivity at 95% specificity (AUC = 0.973). The diagnostic value of the best TM signature (CA-62, CEA and CYFRA 21-1): 100% Specificity, 90% Sensitivity, and 94% test accuracy, AUC=0.990. Conclusions: The results of the study demonstrated that the TM combination allows increasing the Specificity for patients with indeterminate pulmonary nodules detected by CT scans and improves the accuracy of differential diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.